PMID- 22699449
OWN - NLM
STAT- MEDLINE
DCOM- 20121129
LR  - 20161125
IS  - 1421-9824 (Electronic)
IS  - 1420-8008 (Linking)
VI  - 33
IP  - 4
DP  - 2012
TI  - Association between BDNF polymorphism (Val66Met) and executive function in 
      patients with amnestic mild cognitive impairment or mild Alzheimer disease.
PG  - 266-72
LID - 10.1159/000339358 [doi]
AB  - BACKGROUND: In the present study, we examined whether brain-derived neurotrophic 
      factor (BDNF) polymorphism (Val66Met) influenced the changeable executive 
      dysfunction of patients with two separate disease stages: amnestic mild cognitive 
      impairment (A-MCI) or mild Alzheimer disease (AD), which are comparatively 
      similar demented conditions. METHODS: Among 200 outpatients with dementia and 
      MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two 
      genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, 
      based on the representative BDNF functional polymorphism Val66Met. Next, we 
      compared the Frontal Assessment Battery (FAB) total and subtest scores between 
      the two genotypic groups according to each of two different disease stages: A-MCI 
      (n = 42) and mild AD (n = 104). RESULTS: Among patients with only a mild stage of 
      AD, the FAB total and go/no-go scores were significantly lower (p < 0.05) among 
      the subjects with the Val/Val genotype than among the Met carriers. However, no 
      significant differences in any other demographic variables were observed between 
      the genotypes according to each of different disease stages. A significant 
      interaction between Val66Met and age was not observed for the FAB scores. 
      CONCLUSION: These results suggested that the BDNF gene may significantly 
      influence executive dysfunction, including inhibition tasks, among patients with 
      mild-stage AD.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Nagata, Tomoyuki
AU  - Nagata T
AD  - Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan. 
      t.nagata@jikei.ac.jp
FAU - Shinagawa, Shunichiro
AU  - Shinagawa S
FAU - Nukariya, Kazutaka
AU  - Nukariya K
FAU - Yamada, Hisashi
AU  - Yamada H
FAU - Nakayama, Kazuhiko
AU  - Nakayama K
LA  - eng
PT  - Journal Article
DEP - 20120613
PL  - Switzerland
TA  - Dement Geriatr Cogn Disord
JT  - Dementia and geriatric cognitive disorders
JID - 9705200
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/epidemiology/*genetics
MH  - Amino Acid Substitution
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cognition/physiology
MH  - Cognitive Dysfunction/epidemiology/*genetics
MH  - Disease Progression
MH  - Educational Status
MH  - Executive Function/*physiology
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Japan
MH  - Male
MH  - Neuropsychological Tests
MH  - Polymorphism, Genetic/*genetics
EDAT- 2012/06/16 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/16 06:00
PHST- 2012/05/02 00:00 [accepted]
PHST- 2012/06/16 06:00 [entrez]
PHST- 2012/06/16 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 000339358 [pii]
AID - 10.1159/000339358 [doi]
PST - ppublish
SO  - Dement Geriatr Cogn Disord. 2012;33(4):266-72. doi: 10.1159/000339358. Epub 2012 
      Jun 13.